Allarity Therapeutics Inc
Change company Symbol lookup
Select an option...
ALLR Allarity Therapeutics Inc
SIVB SVB Financial Group
LYLT Loyalty Ventures Inc
NMRD Nemaura Medical Inc
LOGI Logitech International SA
BIOC Biocept Inc
KT KT Corp
SVRA Savara Inc
KA Kineta Inc
IMNM Immunome Inc

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology |
Company profile

Allarity Therapeutics, Inc. is a clinical-stage precision medicine company. The Company is engaged in targeting some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates together with its Drug Response Predictor (DRP) companion diagnostics in a precision medicine approach. The Company's products include dovitinib, stenoparib, and IXEMPRA (ixabepilone). The lead therapeutic candidate, dovitinib, is a selective inhibitor of several classes of tyrosine kinases, including FGFR and VEGFR. The therapeutic candidate is stenoparib is a novel inhibitor of the key deoxyribonucleic acid (DNA) damage repair enzyme poly-ADP-ribose polymerase (PARP). The therapeutic candidate is IXEMPRA (ixabepilone) is a selective microtubule inhibitor. The DRP technology is a diagnostic platform that models human tumor biology and can help predict whether a cancer patient respond or not to a particular drug.

Closing Price
Day's Change
0.0389 (37.05%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

OLPX FINAL DEADLINE: Hagens Berman Encourages Olaplex Holdings (OLPX) Investors with Significant Losses to Contact Firm's Attorneys before Jan. 17th Deadline in Securities Class Action

4:00 pm ET January 16, 2023 (Accesswire) Print

SAN FRANCISCO, CA / ACCESSWIRE / January 16, 2023 / Hagens Berman urges Olaplex Holdings, Inc. (NASDAQ:OLPX) investors who suffered significant losses to submit your losses now.

Defined Class: Purchasers in Olaplex Holdings' Sept. 30, 2021 IPO

Lead Plaintiff Deadline: Jan. 17, 2023

Contact An Attorney


Olaplex Holdings, Inc. (NASDAQ:OLPX) Securities Class Action:

The class action has been filed on behalf of investors who purchased Olaplex shares in or traceable to the company's Sept. 30, 2021 initial public offering ("IPO").

Specifically, Olaplex's IPO documents touted its competitive advantages and several significant tailwinds.

According to the complaint, Olaplex's IPO documents misrepresented and failed to disclose that: (1) macro-economic pressures and competition in the haircare market were more robust than the company represented; (2) accordingly, the company was unlikely to maintain its sales and revenue momentum; and, (3) as a result, it was unlikely that the company would be able to achieve the financial and operational growth projected in its offering documents.

Investors began to learn the truth on Sept. 29, 2022, when Piper Sandler published a negative report on Olaplex in which the analyst said, "competition and misinformation are growing risks to the company" and that she anticipated investments in marketing and education were needed to offset the headwinds.

Then, on Oct. 18, 2022, Olaplex announced that it slashed its revenue guidance for FY 2022. The company blamed "a slowdown in sales momentum that it attribute[d] to macro-economic pressures, increased competitive activity including discounting, and a moderation in new customer acquisition, as well as inventory rebalancing across certain customers[.]"

This news sent the price of Olaplex shares crashing over 56% lower on Oct. 19, 2022, closing at $4.24 or nearly 80% below the IPO price.

"We're focused on investors' losses and proving Olaplex's IPO documents misled investors about its growth prospects," said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you invested in Olaplex and have significant losses, or have knowledge that may assist the firm's investigation, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding Olaplex should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email

About Hagens Berman

Hagens Berman is a global plaintiffs' rights complex litigation law firm focusing on corporate accountability through class-action law. The firm is home to a robust securities litigation practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and fraud. More about the firm and its successes can be found at Follow the firm for updates and news at @ClassActionLaw.


Reed Kathrein, 844-916-0895

SOURCE: Hagens Berman Sobol Shapiro LLP

View source version on

comtex tracking


Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.